ArticleJournal of family medicine and primary care2026
Diabetes mellitus, ABO Blood groups, and biochemical correlates in pancreatic cancer- A retrospective study from Jeddah.
Article in Journal of family medicine and primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic cancer (PC) is the seventh-leading cause of cancer-related death worldwide. Studies have established a 2-fold risk of PC among individuals with diabetes mellitus (DM). In this study, we aimed to determine the prevalence and biochemical correlates of DM and in PC patients. Methods: The current retrospective cross-sectional study was conducted between 2016 and 2022. The study sample included all patients aged >18 who were admitted after a primary diagnosis of PC at our center. A comprehensive review of the charts was conducted to gather demographic data, including diabetes and ABO Rh blood group (BG). Results: A total of 186 PC patients were included, 76 (40.9%) of whom were females and 110 (59.1%) were males. DM was found in 120 (64.5%) patients, of whom 125 (67.2%) were diagnosed pre-PC and constituted 72 (60%) males and 48 (40%) females. The most prevalent type of PC was adenocarcinoma (68.6%), with stage IV being 97.8% of the cases. The most common BG among PC patients was type O in 68 (36.6%) patients, followed by type A in 45 (24.2%). Also, 124 (66.7%) were Rh-positive, while 14 (7.5%) were Rh-negative. Serum CA19-9 was the most commonly detected biomarker, present in 27.4% of patients. Conclusion: The percentage of DM among PC patients was found to be 64.5%, of whom 3.8% were diagnosed after the diagnosis of PC. Blood group O was the most common; however BG type B was associated with a higher risk of DM in (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.